Subtype
Malignant Anorectal Neoplasm
CI-CAN-00005864Explore in graph →
452 active trials1 approved drugs6 evidence items
- NCIt
- C215225
Loading cancer entity…
Subtype
CI-CAN-00005864Explore in graph →
Clinical trials
1,783 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (174)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05610163 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS) | active not recruiting | Phase 2 / Phase 3 | 760 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06246344 | Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | active not recruiting | Phase 3 | 128 | Shandong Cancer Hospital and Institute |
| 1 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT04444921 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | active not recruiting | Phase 3 | 205 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03233711 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | active not recruiting | Phase 3 | 344 | National Cancer Institute (NCI)NIH | 2 | Sep 10, 2026 | clinicaltrials |
| NCT04246684 | Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients | active not recruiting | Phase 3 | 702 | Prof. Dr. med. Claus RödelOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06507371 | Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer(mRCAT-III) | active not recruiting | Phase 3 | 170 | Sir Run Run Shaw HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02945566 | Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?(STAR-TREC) | active not recruiting | Phase 2 / Phase 3 | 380 | University of BirminghamOTHER | 5 | Jun 29, 2026 | clinicaltrials |
| NCT01558921 | Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial(RAPIDO) | active not recruiting | Phase 3 | 920 | University Medical Center GroningenOTHER | 7 | May 1, 2026 | clinicaltrials |
| NCT04928807 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) | active not recruiting | Phase 3 | 231 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT04922853 | Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer(COPEC) | active not recruiting | Phase 3 | 554 | West China HospitalOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT02843191 | Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy | active not recruiting | Phase 3 | 358 | Kyung Hee University Hospital at GangdongOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials